文献速递艾滋病与性传播感染

整合酶插入突变的HIV-2突变株复制能力及对整合酶抑制剂表型敏感性的体外分析

In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究通过定点诱变构建HIV-2整合酶突变株,检测其复制能力及对整合酶链转移抑制剂(INSTI)的表型敏感性。携带231ins的病毒复制能力未受损(231ins GIRGK突变株除外),231ins GK对拉替拉韦和卡博特韦耐药但对多替拉韦和比克替拉韦敏感,5个氨基酸插入(GYKGK或SREGK)的突变株对所有INSTI耐药。

要点

  • 231ins突变株复制能力未受损,但231ins GIRGK突变株例外。
  • 231ins GK对拉替拉韦和卡博特韦耐药,对多替拉韦和比克替拉韦仍敏感。
  • 含5个氨基酸插入(GYKGK或SREGK)的突变株对所有INSTI耐药。

核心结论

  • 231ins这一新描述的耐药途径对病毒适应性的影响不可测,并证实对第一代INSTI(拉替拉韦)和卡博特韦的敏感性降低。
  • 含5个氨基酸231ins的突变株对第二代INSTI(多替拉韦和比克替拉韦)出现耐药。

研究设计与样本

  • 通过定点诱变构建HIV-2整合酶突变株并制备病毒 stock,评估复制能力及对INSTI的表型敏感性。

主要发现

  • 携带231ins的病毒未呈现复制能力受损,但231ins GIRGK突变株例外。
  • 231ins GK定点突变株对拉替拉韦和卡博特韦耐药,但对多替拉韦和比克替拉韦仍敏感。
  • 含5个氨基酸插入(GYKGK或SREGK)的定点突变株对 all INSTIs 均耐药。
  • 携带T97A+N155H(伴或不伴E92Q)的定点突变株对 all INSTIs 耐药,但比克替拉韦除外。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-2 resistance to integrase strand-transfer inhibitors (INSTIs) is characterized by two main pathways: (i) mutations at codons 143, 148 and155; and (ii) amino acid insertion after integrase codon 231 (231ins). OBJECTIVES: To complete INSTI resistance data on HIV-2 by determining the viral replicative capacity and INSTI phenotypic susceptibility of integrase mutants obtained through site-directed mutagenesis. METHODS: Site-directed mutants (SDMs) were constructed and viral stocks produced. Viral replicative capacity was assessed by measuring HIV-2 viral load at days 3, 7 and 14. In vitro phenotypic susceptibility was measured using the ANRS PBMC assay. RESULTS: Viruses bearing 231ins did not present impaired replicative capacity, except the 231ins GIRGK mutant. A 231ins GK SDM was resistant to raltegravir and cabotegravir, but remained susceptible to dolutegravir and bictegravir. SDMs harbouring a 5 amino acid insertion (GYKGK or SREGK) were both resistant to all INSTIs. The SDM with T97A+N155H, with or without E92Q, was resistant to all INSTIs, except bictegravir. CONCLUSIONS: These first data on the newly described resistance pathway 231ins, using site-directed mutagenesis, showed no measurable impact on viral fitness and confirmed the decreased susceptibility to a first-generation INSTI (raltegravir) and cabotegravir. Resistance to second-generation INSTIs (dolutegravir and bictegravir) occurred for mutants with a 5 amino acid 231ins.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Le Hingrat Q, Collin G, Damond F, et al. In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions. J Antimicrob Chemother. 2022. PMID: 34741606. doi:10.1093/jac/dkab387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。